Quality and Quantity of Diffuse and Focal White Matter Disease and Cognitive Disability of Patients with Multiple Sclerosis
Giuseppe Bomboi MD
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorVasiliki N. Ikonomidou PhD
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorStefano Pellegrini PhD
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorSusan K. Stern BA
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorAntonio Gallo MD
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorSungyoung Auh PhD
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorIordanis E. Evangelou DPhil
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorJhalak Agarwal
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorClelia Pellicano MD
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorJoan M. Ohayon CRNP
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorFredric K. Cantor MD
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorMary Ehrmantraut CRNP
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorHenry F. McFarland MD
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorRobert L. Kane PhD
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorFrancesca Bagnato MD, PhD
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorGiuseppe Bomboi MD
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorVasiliki N. Ikonomidou PhD
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorStefano Pellegrini PhD
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorSusan K. Stern BA
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorAntonio Gallo MD
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorSungyoung Auh PhD
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorIordanis E. Evangelou DPhil
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorJhalak Agarwal
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorClelia Pellicano MD
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorJoan M. Ohayon CRNP
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorFredric K. Cantor MD
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorMary Ehrmantraut CRNP
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorHenry F. McFarland MD
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorRobert L. Kane PhD
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorFrancesca Bagnato MD, PhD
From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (GB, VNI, SP, SKS, AG, IEE, JA, CP, JMO, FKC, ME, HFM, FB); Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD (SA); VA Maryland Healthcare System (RLK).
Search for more papers by this authorJ Neuroimaging 2011;21:e57-e63.
Abstract
ABSTRACT
BACKGROUND AND PURPOSE
Using high-field magnetic resonance imaging (MRI), we investigated the relationships between white matter (WM) lesion volume (LV), normal-appearing WM (NAWM) normalized volume, WM-lesion and NAWM magnetization transfer ratios (MTRs), brain parenchyma fraction (BPF), and cognitive impairment (CI) in multiple sclerosis (MS).
METHODS
Twenty-four patients and 24 healthy volunteers (age, sex, and years of education–matched) underwent a 3.0 Tesla (3T) scan and evaluation of depression, fatigue, and CI using the Minimal Assessment of Cognitive Function in MS (MACFIMS) battery.
RESULTS
In this clinically relatively well-preserved cohort of patients (median score on the Expanded Disability Status Scale = 1.5), CI was detected on Symbol Digit Modalities Test (SDMT), California Verbal Learning Test-II (CVLT-II), and Controlled Oral Word Association Test. MT data were available in 19 pairs on whom correlation analyses were performed. Associations were seen between SDMT and normalized NAWM volume (P= .034, r= .502), CVLT-II long delay and normalized NAWM volume (P= .012, r= .563), WM-LV (P= .024, r= .514), and BPF (P= .002, r= .666).
CONCLUSIONS
The use of 3T MRI in a sample of clinically stable MS patients shows the importance of WM disease in hampering processing speed and word retrieval.
References
- 1 Patti F. Cognitive impairment in multiple sclerosis. Mult Scler 2009; 15: 2-8.
- 2 Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol 2008; 7: 1139-1151.
- 3 Amato MP, Zipoli V, Portaccio E. Multiple sclerosis-related cognitive change: a review of cross-sectional and longitudinal studies. J Neurol Sci 2006; 245: 41-46.
- 4 Filippi M. Magnetic resonance imaging correlates of cognitive dysfunction in patients with multiple sclerosis. Rev Neurol 2006; 30: 1253-1256.
- 5 Filippi M, Tortorella C, Rovaris M, et al. Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 68: 157-161.
- 6 Zivadinov R, De Masi R, Nasuelli D, et al. MRI techniques and cognitive impairment in the early phase of relapsing-remitting multiple sclerosis. Neuroradiology 2001; 43: 272-278.
- 7 Deloire MS, Salort E, Bonnet M, et al. Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76: 519-526.
- 8 Summers M, Fisniku L, Anderson V, et al. Cognitive impairment in relapsing-remitting multiple sclerosis can be predicted by imaging performed several years earlier. Mult Scler 2008; 14: 197-204.
- 9 Glanz BI, Holland CM, Gauthier SA, et al. Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis. Mult Scler 2007; 13: 1004-1010.
- 10 Benedict RH, Fischer JS, Archibald CJ, et al. Minimal neuropsychological assessment of MS patients: a consensus approach. Clin Neuropsychol 2002; 16: 381-397.
- 11 McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for MS. Ann Neurol 2001; 50: 121-127.
- 12 Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
- 13 Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871-882.
- 14 Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehabil 1988; 69: 850-854.
- 15 Smith A. Symbol Digit Modalities Test. Los Angeles , CA : Western Psychological Services, 1982.
- 16 Delis DC, Kramer JH, Kaplan E, et al. California Verbal Learning Test: Adult Version. San Antonio , TX : The Psychological Corporation, 1987.
- 17 Benedict RHB. Brief Visuospatial Memory Test: Revised— Professional Manual. Odessa , FL : Psychological Assessment Resources Inc, 1997.
- 18 Delis DC, Kaplan E, Kramer JH. Delis-Kaplan. Executive Function System (D-KEFS). San Antonio , TX : The Psychological Corporation, 2001.
- 19 Benton AL, Hamsher K, Varney NR, et al. Judgement of Line Orientation. Oxford , UK : Oxford University Press Inc, 1983.
- 20 Benton AL, Hamsher K, Sivan AB. Multilingual Aphasia Examination. Iowa City , IO : AJA Associates, 1994.
- 21 Gronwall DMA. Paced auditory serial addition task: a measure of recovery from concussion. Percept Mot Skills 1977; 44: 367-373.
- 22 Solari A, Radice D, Manneschi L, et al. The multiple sclerosis functional composite: different practice effects in the three test components. J Neurol Sci 2005; 228: 71-74.
- 23 Fisk JD, Ritvo PG, Ross L, et al. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994; 18: 79-83.
- 24 Flachenecker P, Kümpfel T, Kallmann B, et al. Fatigue in multiple sclerosis: a comparison of different scales and correlation to clinical parameters. Mult Scler 2002; 8: 23-26.
- 25 Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl-Psychol-Meas 1977; 1: 385-401.
- 26 Wilkinson GS. The Wide Range Achievement Test: Manual. 3rd ed. Wilmington , DE : Wide Range, 1993.
- 27 Richert ND, Ostuni JL, Bash CN, et al. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Mult Scler 2001; 7: 49-58.
- 28 Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002; 33: 341-355.
- 29 Fischl B, Salat DH, Van Der Kouwe AJ, et al. Sequence-independent segmentation of magnetic resonance images. Neuroimage 2004; 23: 69-84.
- 30 Fischl B, Sereno MI, Dale AM. Cortical surface-based analysis. II: inflation, flattening, and a surface-based coordinate system. Neuroimage 1999; 9: 195-207.
- 31
Fischl B,
Sereno MI,
Tootell RB, et al.
High-resolution intersubject averaging and a coordinate system for the cortical surface.
Hum Brain Mapp
1999; 8: 272-284.
10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4 CAS PubMed Web of Science® Google Scholar
- 32 Collins DL, Neelin P, Peters TM, et al. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr 1994; 18: 192-205.
- 33 Stollberger R, Wach P. Imaging of the active B1 field in vivo. Magn Reson Med 1996; 35: 246-251.
- 34 Ropele S, Filippi M, Valsasina P, et al. Assessment and correction of B1-induced errors in magnetization transfer ratio measurements. Magn Reson Med 2005; 53: 134-140.
- 35 Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002; 17: 479-489.
- 36 Stevenson VL, Smith SM, Matthews PM, et al. Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral atrophy. J Neurol 2006; 249: 171-177.
- 37 Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1133-1142.
- 38 DeSousa EA, ALbert RH, Kalman B. Cognitive impairments in multiple sclerosis. Am J Alzheimers Dis Other Demen 2002; 17: 23-29.
- 39 Benedict RH, Cookfair D, Gavett R, et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 2006; 12: 549-558.
- 40 Fountoulakis KN, Bech P, Panagiotidis P, et al. Comparison of depressive indices: reliability, validity, relationship to anxiety and personality and the role of age and life events. J Affect Disord 2007; 97: 187-195.
- 41 Shean G, Baldwin G. Sensitivity and specificity of depression questionnaires in a college-age sample. J Genet Psychol 2008; 169: 281-288.
- 42 Sastre-Garriga J, Arévalo MJ, Renom M, et al. Brain volumetry counterparts of cognitive impairment in patients with multiple sclerosis. J Neurol Sci 2009; 282: 120-124.
- 43 McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007; 8: 913-919.
- 44 Stankiewicz JM, Glanz BI, Healy BC, et al. Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. J Neuroimaging 2009; epub ahead of print.
- 45 Dineen RA, Vilisaar J, Hlinka J, et al. Disconnection as a mechanism for cognitive dysfunction in multiple sclerosis. Brain 2009; 132: 239-249.
- 46 Houtchens MK, Benedict RH, Killiany R, et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology 2007; 69: 1213-1222.
- 47 Wood AG, Saling MM, Abbott DF, et al. A neurocognitive account of frontal lobe involvement in orthographic lexical retrieval: an fMRI study. Neuroimage 2001; 14: 162-169.
- 48 Rovaris M, Comi G, Filippi M. MRI markers of destructive pathology in multiple sclerosis-related cognitive dysfunction. J Neurol Sci 2006; 15: 111-116.
Citing Literature
